Abstract Number: 1731 • 2018 ACR/ARHP Annual Meeting
Vertebral Fracture Prevalence and Measurement of the Scanographic Bone Attenuation Coefficient on CT-Scan in 70 Patients with Systemic Scleroderma
Background/Purpose: Osteoporosis screening is not systematic in sclerodermic patients but some studies demonstrated a similar risk between rheumatoid arthritis and systemic scleroderma [1,2,3]. Thoracic and/or…Abstract Number: 1732 • 2018 ACR/ARHP Annual Meeting
Alterations of Body Composition in Patients with Systemic Scleroderma Are Associated with Disease Activity, Physical Activity and Serum Levels of Inflammatory Cytokines
Background/Purpose: Fibrosis of the skin and visceral organs, especially digestive tract, and musculoskeletal involvement in systemic sclerosis (SSc) can have a negative impact on body…Abstract Number: 1733 • 2018 ACR/ARHP Annual Meeting
Should We Perform Exercise Echocardiogram As a Screening Test for Pulmonary Arterial Hypertension (PAH) for All Systemic Sclerosis (SSc) Patients?
Background/Purpose: Prevalence of pulmonary arterial hypertension (PAH) in systemic sclerosis (SSc) is 8-12%, and 3-year survival rate is 47-56%. Rest echocardiogram is used to screen…Abstract Number: 1734 • 2018 ACR/ARHP Annual Meeting
Association of Short-Term Longitudinal Changes in Clinical and Physiologic Variables with Overall Survival in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
Background/Purpose: Interstitial lung disease (ILD) is one of the leading causes of morbidity and mortality in patients with SSc. However, the impact of changes in…Abstract Number: 1735 • 2018 ACR/ARHP Annual Meeting
Diagnostic Accuracy of MR Angiography in a Cohort with Systemic Sclerosis Compared to Other Rheumatic Diseases with Acral Hypoperfusion
Background/Purpose: Vasculopathy is a major feature of systemic sclerosis (SSc). It leads to intimal proliferation and adventitial fibrosis of small and large arterial blood vessels.…Abstract Number: 1736 • 2018 ACR/ARHP Annual Meeting
Incidence and Risk Factors for Gangrene in Patients with Systemic Sclerosis from the Eustar Cohort
Background/Purpose: In patients with systemic sclerosis (SSc), peripheral vasculopathy can promote critical ischemia and gangrene that are very severe complications with potential life-threatening consequences. Recently…Abstract Number: 1737 • 2018 ACR/ARHP Annual Meeting
Multiplexed Autoantibody Profiles in a Systemic Sclerosis Clinical Trial Comparing Autologous Hematopoietic Stem Cell Transplantation and Cyclophosphamide
Background/Purpose: In a randomized, open-label, phase II clinical trial (SCOT, Scleroderma: Cyclophosphamide or Transplantation)1, subjects were randomly assigned to treatment with myeloablative CD34+ selected autologous…Abstract Number: 1738 • 2018 ACR/ARHP Annual Meeting
Detect Outperforms Echocardiography Based Screening Guidelines for Early Detection of Systemic Sclerosis Associated Pulmonary Arterial Hypertension
Background/Purpose: Pulmonary arterial hypertension (PAH) is a leading cause of mortality in patients with systemic sclerosis (SSc). Active screening can detect SSc-PAH earlier and may…Abstract Number: 1739 • 2018 ACR/ARHP Annual Meeting
What Do Patient Reported Outcomes for Routine Monitoring of Gastrointestinal Tract Symptoms in a Systemic Sclerosis Center Tell Us about Clinical Features of Potential Small Intestinal Bacterial Overgrowth?
Background/Purpose: The implementation of patient reported outcome measures (PROMs) is increasingly recognized as a critical aspect of clinical practice. The use of gastrointestinal (GI) PROMs…Abstract Number: 1740 • 2018 ACR/ARHP Annual Meeting
Effectiveness and Safety of Tocilizumab for the Treatment of Refractory Systemic Sclerosis Associated Interstitial Lung Disease: A Case Series
Background/Purpose: To evaluate the efficacy and safety of TCZ as as a rescue therapy in patients with refractory scleroderma-associated interstitial lung disease (SSc-ILD). Methods: We…Abstract Number: 1741 • 2018 ACR/ARHP Annual Meeting
Disease Duration and Autoantibodies Predict Distinct Skin Score Trajectories in Diffuse Cutaneous Systemic Sclerosis
Background/Purpose: Although severity of skin involvement and change in skin thickness over time vary substantially between patients with diffuse cutaneous systemic sclerosis (dcSSc), for the…Abstract Number: 1742 • 2018 ACR/ARHP Annual Meeting
Disease-Specific Autoantibodies Associate with Remarkably Different Risk of Development of Significant Lung Fibrosis in Systemic Sclerosis
Background/Purpose: Pulmonary fibrosis (PF) is a leading cause of disease-related death in SSc patients. Some studies suggest that the timing of PF development differs between…Abstract Number: 1743 • 2018 ACR/ARHP Annual Meeting
Serum Markers Potentially Associated with PAH in Systemic Sclerosis; A Targeted Screening Approach
Background/Purpose: Pulmonary arterial hypertension (PAH) is a feared complication in systemic sclerosis (SSc). Detection of PAH at a preclinical stage is important as early diagnosis…Abstract Number: 1744 • 2018 ACR/ARHP Annual Meeting
Prognostic Value of Right Heart Involvement in Systemic Sclerosis:Not Only Pulmonary Arterial Hypertension
Background/Purpose: In SSc, cardiac dysfunction is associated with poor prognosis. Right ventricular involvement is frequently secondary to PAH. Echocardiography is the routine imaging tool to…Abstract Number: 1745 • 2018 ACR/ARHP Annual Meeting
Efficacy of Eosinophilic Granulomatosis with Polyangiitis (Churg–Strauss) Treatments According to the Type of Manifestations Based on Analysis of 376 Patients
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) (Churg–Strauss) is a small-vessel necrotizing vasculitis characterized by blood and tissue eosinophilia and asthma. Glucocorticoids (GCs) represent the cornerstone…
ACR Meeting Abstracts